Abstract
Groups of 122 Peruvian adults of low socioeconomic level (SEL) and 125 of high SEL received a randomly allocated 5 x 10(9)- or 5 x 10(8)-CFU dose of CVD 103-HgR live oral cholera vaccine or a placebo. The vaccine was well tolerated. Vibriocidal seroconversions occurred in 78% of high-SEL and 72% of low-SEL subjects who ingested the high dose and in 78 and 49%, respectively, of those who received the low dose.
Publication types
-
Clinical Trial
-
Randomized Controlled Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Administration, Oral
-
Adult
-
Antibodies, Bacterial / blood*
-
Cholera Vaccines / administration & dosage
-
Cholera Vaccines / adverse effects
-
Cholera Vaccines / immunology*
-
Double-Blind Method
-
Humans
-
Peru
-
Socioeconomic Factors
-
Vaccination
-
Vibrio cholerae / immunology*
Substances
-
Antibodies, Bacterial
-
Cholera Vaccines